Damiano Buratto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Damiano Buratto has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Ruhong Zhou
Zhejiang University
5 shared publications - Francesco Zonta
Department of Biosciences and Bioinformatics, Xi'an Jiaotong-Liverpool University, Suzhou, Jiangsu, 215123, China
4 shared publications - Dong Zhang
Institute of Quantitative Biology, College of Life Sciences, Zhejiang University
2 shared publications - Wanding Wang2 shared publications
Yangwei Jiang
College of Life Sciences (X.D., Y.J., C.L., Z.K., L.F., Z. Lei, H.C., Y.D., C.S., X.S., D.B., A.L., J.S., D.Z., R.Z., Q.Y.), Zhejiang University, Hangzhou, China
2 shared publications- Aifu Lin
MOE Laboratory of Biosystem Homeostasis and Protection, College of Life Sciences, Zhejiang University, Hangzhou, China
1 shared publication
Latest Publications
- 30 January 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 138 (3)
Novel DNJ Derivative Ameliorates Cardiac Hypertrophy by Targeting OPA1 and Restoring Mitochondrial Health
BACKGROUND: Pathological cardiac hypertrophy, an abnormal enlargement of cardiomyocytes and interstitial fibrosis in response to sustained injury or pressure overload, may lead to heart failure or even sudden death. Affected patients often also exhibit myocardial mitochondrial dysfunction and associated structural damage. Discovering more potent mitochondria-targeting compounds may therefore hold great benefit, both for elucidating the mechanisms of cardiac hypertrophy and for treating affected patients. METHODS: A series of novel 1-deoxynojirimycin (DNJ) derivatives was designed based on the unique binding mode of DNJ with OPA1 (optic atrophy 1). Two-step phenotypic screening was then performed using patient-specific cytoplasmic hybrid cells and iPSC-derived cardiomyocytes to identify promising candidates. Molecular dynamics simulations, combined with proteomic, biochemical, and physiological assays, were used to assess potential therapeutic mechanisms for mitochondrial disorders. OPA1 mutant cell lines were established to test candidate compound target specificity. Pathological cardiac hypertrophy models were established in mice and rats through angiotensin II induction and abdominal aortic constriction, enabling comprehensive evaluation of the candidates’ preventive and therapeutic efficacy. RESULTS: DNJ occupies a cavity formed by the GTPase domain of the OPA1 dimer, acting as an additional linker at the dimeric OPA1 interface. Here, we have designed and identified a novel DNJ derivative, DNJ5a. Compared with DNJ, DNJ5a exhibits enhanced in silico and in vitro binding specificity, providing additional anchor sites for direct OPA1 interaction. This interaction facilitates the stabilization of the OPA1 dimeric form to repair mitochondrial cristae damage and maintain inner membrane integrity. Comprehensive improvements in mitochondrial bioenergetics, Ca 2+ homeostasis, mitophagy, and multidimensional functional responses are seen to result. In 2 rodent animal cardiac hypertrophy models, DNJ5a administration showed excellent preventive and therapeutic efficacy towards promoting mitochondrial health and cardiac function in vivo. CONCLUSIONS: Unlike conventional mitochondrial drugs, which act to alleviate specific dysfunctions, DNJ5a can specifically target OPA1-GTPase and comprehensively improve mitochondrial health to ameliorate cardiac hypertrophy. These findings underscore mitochondrial abnormality as a primary contributor to pathological cardiac remodeling and present OPA1 as a strong potential drug target. The underlying mechanism of this novel agonist DNJ5a may pave the way towards developing many other promising mitochondrial-targeted therapeutics.
- 30 January 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 138 (3)
Novel DNJ Derivative Ameliorates Cardiac Hypertrophy by Targeting OPA1 and Restoring Mitochondrial Health
BACKGROUND: Pathological cardiac hypertrophy, an abnormal enlargement of cardiomyocytes and interstitial fibrosis in response to sustained injury or pressure overload, may lead to heart failure or even sudden death. Affected patients often also exhibit myocardial mitochondrial dysfunction and associated structural damage. Discovering more potent mitochondria-targeting compounds may therefore hold great benefit, both for elucidating the mechanisms of cardiac hypertrophy and for treating affected patients. METHODS: A series of novel 1-deoxynojirimycin (DNJ) derivatives was designed based on the unique binding mode of DNJ with OPA1 (optic atrophy 1). Two-step phenotypic screening was then performed using patient-specific cytoplasmic hybrid cells and iPSC-derived cardiomyocytes to identify promising candidates. Molecular dynamics simulations, combined with proteomic, biochemical, and physiological assays, were used to assess potential therapeutic mechanisms for mitochondrial disorders. OPA1 mutant cell lines were established to test candidate compound target specificity. Pathological cardiac hypertrophy models were established in mice and rats through angiotensin II induction and abdominal aortic constriction, enabling comprehensive evaluation of the candidates’ preventive and therapeutic efficacy. RESULTS: DNJ occupies a cavity formed by the GTPase domain of the OPA1 dimer, acting as an additional linker at the dimeric OPA1 interface. Here, we have designed and identified a novel DNJ derivative, DNJ5a. Compared with DNJ, DNJ5a exhibits enhanced in silico and in vitro binding specificity, providing additional anchor sites for direct OPA1 interaction. This interaction facilitates the stabilization of the OPA1 dimeric form to repair mitochondrial cristae damage and maintain inner membrane integrity. Comprehensive improvements in mitochondrial bioenergetics, Ca 2+ homeostasis, mitophagy, and multidimensional functional responses are seen to result. In 2 rodent animal cardiac hypertrophy models, DNJ5a administration showed excellent preventive and therapeutic efficacy towards promoting mitochondrial health and cardiac function in vivo. CONCLUSIONS: Unlike conventional mitochondrial drugs, which act to alleviate specific dysfunctions, DNJ5a can specifically target OPA1-GTPase and comprehensively improve mitochondrial health to ameliorate cardiac hypertrophy. These findings underscore mitochondrial abnormality as a primary contributor to pathological cardiac remodeling and present OPA1 as a strong potential drug target. The underlying mechanism of this novel agonist DNJ5a may pave the way towards developing many other promising mitochondrial-targeted therapeutics.
- Open Access
ANUBI: A Platform for Affinity Optimization of Proteins and Peptides in Drug Design
The increasing availability of computational power is opening unprecedented opportunities in computational biology and drug design. Computer simulations based on physical models can now reproduce or replace critical biophysical experiments such as binding affinity evaluations in the drug screening process. Here we present ANUBI (ANUBI Nexus for Understanding Binding Interactions), a software package that automates sequence space exploration and binding free energy calculations to optimize protein or peptide drug candidates for improved target binding. Starting from a user-provided molecular model of the drug-target interaction, ANUBI systematically evaluates point mutations in selected regions using Monte Carlo methodology, retaining favorable mutations based on calculated binding affinity differences. We demonstrate that this approach efficiently samples sequence space, generating dozens of optimized variants in timeframes comparable to experimental approaches at substantially reduced cost. As proof of concept, we applied ANUBI to an antibody-antigen complex and a peptide-protein interaction, identifying variants with significantly improved predicted binding energy (approximately 20 kcal/mol, calculated using the MMPBSA method), within 20 days of computation on a single GPU. Abstract Figure: TOC GRAPHIC:
Open AccessANUBI: A Platform for Affinity Optimization of Proteins and Peptides in Drug Design
The increasing availability of computational power is opening unprecedented opportunities in computational biology and drug design. Computer simulations based on physical models can now reproduce or replace critical biophysical experiments such as binding affinity evaluations in the drug screening process. Here we present ANUBI (ANUBI Nexus for Understanding Binding Interactions), a software package that automates sequence space exploration and binding free energy calculations to optimize protein or peptide drug candidates for improved target binding. Starting from a user-provided molecular model of the drug-target interaction, ANUBI systematically evaluates point mutations in selected regions using Monte Carlo methodology, retaining favorable mutations based on calculated binding affinity differences. We demonstrate that this approach efficiently samples sequence space, generating dozens of optimized variants in timeframes comparable to experimental approaches at substantially reduced cost. As proof of concept, we applied ANUBI to an antibody-antigen complex and a peptide-protein interaction, identifying variants with significantly improved predicted binding energy (approximately 20 kcal/mol, calculated using the MMPBSA method), within 20 days of computation on a single GPU. Abstract Figure: TOC GRAPHIC:
- Open Access
Assessing computational strategies for the evaluation of antibody binding affinities
Accurate evaluation of binding affinity is critical in drug discovery to identify molecules that bind strongly to their targets while minimizing off-target effects. Although binding affinity calculations are theoretically well-defined, they require exhaustive sampling of configurational space, a step that often requires significant computational resources. In this study, we compare different methods for calculating the binding energy of antibodies targeting a peptide derived from the N-terminus of CXCR2, a GPCR-family protein. Contrary to some previous reports, we find that equilibrium MMPBSA calculations yield better agreement with experimental binding affinities than non-equilibrium potential of mean force evaluations, underscoring the system-dependent performance of these methods. We also observed a modest improvement in accuracy when MMPBSA is combined with replica exchange molecular dynamics, albeit at a significantly higher computational cost. Calculation based on Rosetta force field, instead, produced results that did not correlate with the experimental data. We attribute these findings to two factors, which could limit the applicability of some methodologies that are widely used in the computation the binding energy: the high potency of the antibodies studied and the dominance of hydrophobic interactions between the antibodies and the peptide. Overall, this work provides important insights for optimizing in silico antibody screening strategies.
Open AccessAssessing computational strategies for the evaluation of antibody binding affinities
Accurate evaluation of binding affinity is critical in drug discovery to identify molecules that bind strongly to their targets while minimizing off-target effects. Although binding affinity calculations are theoretically well-defined, they require exhaustive sampling of configurational space, a step that often requires significant computational resources. In this study, we compare different methods for calculating the binding energy of antibodies targeting a peptide derived from the N-terminus of CXCR2, a GPCR-family protein. Contrary to some previous reports, we find that equilibrium MMPBSA calculations yield better agreement with experimental binding affinities than non-equilibrium potential of mean force evaluations, underscoring the system-dependent performance of these methods. We also observed a modest improvement in accuracy when MMPBSA is combined with replica exchange molecular dynamics, albeit at a significantly higher computational cost. Calculation based on Rosetta force field, instead, produced results that did not correlate with the experimental data. We attribute these findings to two factors, which could limit the applicability of some methodologies that are widely used in the computation the binding energy: the high potency of the antibodies studied and the dominance of hydrophobic interactions between the antibodies and the peptide. Overall, this work provides important insights for optimizing in silico antibody screening strategies.
- Open Access
In silico design and validation of high-affinity RNA aptamers for SARS-CoV-2 comparable to neutralizing antibodies
Nucleic acid aptamers hold promise for clinical applications, yet understanding their molecular binding mechanisms to target proteins and efficiently optimizing their binding affinities remain challenging. Here, we present CAAMO (Computer-Aided Aptamer Modeling and Optimization), which integrates in silico aptamer design with experimental validation to accelerate the development of aptamer-based RNA therapeutics. Starting from the sequence information of a reported RNA aptamer, Ta, for the SARS-CoV-2 spike protein, our CAAMO method first determines its binding mode with the spike protein’s receptor binding domain (RBD) through a multi-strategy computational approach. We then optimize its binding affinity via structure-based rational design. Among the six designed candidates, five were experimentally verified and exhibited enhanced binding affinities compared to the original Ta sequence. Furthermore, we directly compared the binding properties of the RNA aptamers to neutralizing antibodies, and found that the designed aptamer Ta G34C demonstrated a comparable binding affinity to the RBD compared to the representative neutralizing antibodies analyzed in this study. This highlights its potential as an alternative to existing COVID-19 antibodies. Our work provides a robust approach for the efficient design of a relatively large number of high-affinity aptamers with complicated topologies. This approach paves the way for the development of aptamer-based RNA diagnostics and therapeutics.
Open AccessIn silico design and validation of high-affinity RNA aptamers for SARS-CoV-2 comparable to neutralizing antibodies
Nucleic acid aptamers hold promise for clinical applications, yet understanding their molecular binding mechanisms to target proteins and efficiently optimizing their binding affinities remain challenging. Here, we present CAAMO (Computer-Aided Aptamer Modeling and Optimization), which integrates in silico aptamer design with experimental validation to accelerate the development of aptamer-based RNA therapeutics. Starting from the sequence information of a reported RNA aptamer, Ta, for the SARS-CoV-2 spike protein, our CAAMO method first determines its binding mode with the spike protein’s receptor binding domain (RBD) through a multi-strategy computational approach. We then optimize its binding affinity via structure-based rational design. Among the six designed candidates, five were experimentally verified and exhibited enhanced binding affinities compared to the original Ta sequence. Furthermore, we directly compared the binding properties of the RNA aptamers to neutralizing antibodies, and found that the designed aptamer Ta G34C demonstrated a comparable binding affinity to the RBD compared to the representative neutralizing antibodies analyzed in this study. This highlights its potential as an alternative to existing COVID-19 antibodies. Our work provides a robust approach for the efficient design of a relatively large number of high-affinity aptamers with complicated topologies. This approach paves the way for the development of aptamer-based RNA diagnostics and therapeutics.
- Open Access
- 5 December 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
An inorganic mineral-based protocell with prebiotic radiation fitness
Protocell fitness under extreme prebiotic conditions is critical in understanding the origin of life. However, little is known about protocell’s survival and fitness under prebiotic radiations. Here we present a radioresistant protocell model based on assembly of two types of coacervate droplets, which are formed through interactions of inorganic polyphosphate (polyP) with divalent metal cation and cationic tripeptide, respectively. Among the coacervate droplets, only the polyP-Mn droplet is radiotolerant and provides strong protection for recruited proteins. The radiosensitive polyP-tripeptide droplet sequestered with both proteins and DNA could be encapsulated inside the polyP-Mn droplet, and form into a compartmentalized protocell. The protocell protects the inner nucleoid-like condensate through efficient reactive oxygen species’ scavenging capacity of intracellular nonenzymic antioxidants including Mn-phosphate and Mn-peptide. Our results demonstrate a radioresistant protocell model with redox reaction system in response to ionizing radiation, which might enable the protocell fitness to prebiotic radiation on the primitive Earth preceding the emergence of enzyme-based fitness. This protocell might also provide applications in synthetic biology as bioreactor or drug delivery system.
- 5 December 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
Open AccessAn inorganic mineral-based protocell with prebiotic radiation fitness
Protocell fitness under extreme prebiotic conditions is critical in understanding the origin of life. However, little is known about protocell’s survival and fitness under prebiotic radiations. Here we present a radioresistant protocell model based on assembly of two types of coacervate droplets, which are formed through interactions of inorganic polyphosphate (polyP) with divalent metal cation and cationic tripeptide, respectively. Among the coacervate droplets, only the polyP-Mn droplet is radiotolerant and provides strong protection for recruited proteins. The radiosensitive polyP-tripeptide droplet sequestered with both proteins and DNA could be encapsulated inside the polyP-Mn droplet, and form into a compartmentalized protocell. The protocell protects the inner nucleoid-like condensate through efficient reactive oxygen species’ scavenging capacity of intracellular nonenzymic antioxidants including Mn-phosphate and Mn-peptide. Our results demonstrate a radioresistant protocell model with redox reaction system in response to ionizing radiation, which might enable the protocell fitness to prebiotic radiation on the primitive Earth preceding the emergence of enzyme-based fitness. This protocell might also provide applications in synthetic biology as bioreactor or drug delivery system.
- Open Access
- 7 November 2023
- Published by Springer Nature in Research Square
Dynamic topology-mediated maturation of β-barrel proteins in BAM-catalyzed folding
BamA is an essential component of the β-barrel assembly complex (BAM) that catalyzes the insertion and assembly of β-barrel outer membrane proteins (OMPs) in Gram-negative bacteria. BamA adopts two distinct conformations: the inward-open and outward-open β-barrels, regulated by periplasmic domains during different folding stages. However, it remains unclear how these conformational shifts promote the maturation of OMPs. Drawing from our prior work1, we identify a novel folding intermediate, characterized by an inward-open BamA and a non-closing OMP. This intermediate attains stability via enhanced hydrophobic interactions accompanying the topological alterations of the hybrid-barrel. The subsequent folding events of the hybrid-barrel are then sampled through molecular dynamics simulations augmented with enhanced sampling. Remarkably, our observations reveal that the spontaneous closure and separation are regulated by an induced-fit mechanism and supplementary hydrophobic interactions, prominently from the extracellular loop 1 (BL1) of BamA. Further cell viability assays confirm that disruption to BL1’s topology compromises BamA functionality and is detrimental to the bacteria. Taken together, our findings provide insights into the significance of BamA’s dynamic topological shifts during OMP maturation.
- 7 November 2023
- Published by Springer Nature in Research Square
Open AccessDynamic topology-mediated maturation of β-barrel proteins in BAM-catalyzed folding
BamA is an essential component of the β-barrel assembly complex (BAM) that catalyzes the insertion and assembly of β-barrel outer membrane proteins (OMPs) in Gram-negative bacteria. BamA adopts two distinct conformations: the inward-open and outward-open β-barrels, regulated by periplasmic domains during different folding stages. However, it remains unclear how these conformational shifts promote the maturation of OMPs. Drawing from our prior work1, we identify a novel folding intermediate, characterized by an inward-open BamA and a non-closing OMP. This intermediate attains stability via enhanced hydrophobic interactions accompanying the topological alterations of the hybrid-barrel. The subsequent folding events of the hybrid-barrel are then sampled through molecular dynamics simulations augmented with enhanced sampling. Remarkably, our observations reveal that the spontaneous closure and separation are regulated by an induced-fit mechanism and supplementary hydrophobic interactions, prominently from the extracellular loop 1 (BL1) of BamA. Further cell viability assays confirm that disruption to BL1’s topology compromises BamA functionality and is detrimental to the bacteria. Taken together, our findings provide insights into the significance of BamA’s dynamic topological shifts during OMP maturation.
- Open Access
- 13 September 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (9) , 1285
In Silico Maturation of a Nanomolar Antibody against the Human CXCR2
The steady increase in computational power in the last 50 years is opening unprecedented opportunities in biology, as computer simulations of biological systems have become more accessible and can reproduce experimental results more accurately. Here, we wanted to test the ability of computer simulations to replace experiments in the limited but practically useful scope of improving the biochemical characteristics of the abN48 antibody, a nanomolar antagonist of the CXC chemokine receptor 2 (CXCR2) that was initially selected from a combinatorial antibody library. Our results showed a good correlation between the computed binding energies of the antibody to the peptide target and the experimental binding affinities. Moreover, we showed that it is possible to design new antibody sequences in silico with a higher affinity to the desired target using a Monte Carlo Metropolis algorithm. The newly designed sequences had an affinity comparable to the best ones obtained using in vitro affinity maturation and could be obtained within a similar timeframe. The methodology proposed here could represent a valid alternative for improving antibodies in cases in which experiments are too expensive or technically tricky and could open an opportunity for designing antibodies for targets that have been elusive so far.
- 13 September 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (9) , 1285
Open AccessIn Silico Maturation of a Nanomolar Antibody against the Human CXCR2
The steady increase in computational power in the last 50 years is opening unprecedented opportunities in biology, as computer simulations of biological systems have become more accessible and can reproduce experimental results more accurately. Here, we wanted to test the ability of computer simulations to replace experiments in the limited but practically useful scope of improving the biochemical characteristics of the abN48 antibody, a nanomolar antagonist of the CXC chemokine receptor 2 (CXCR2) that was initially selected from a combinatorial antibody library. Our results showed a good correlation between the computed binding energies of the antibody to the peptide target and the experimental binding affinities. Moreover, we showed that it is possible to design new antibody sequences in silico with a higher affinity to the desired target using a Monte Carlo Metropolis algorithm. The newly designed sequences had an affinity comparable to the best ones obtained using in vitro affinity maturation and could be obtained within a similar timeframe. The methodology proposed here could represent a valid alternative for improving antibodies in cases in which experiments are too expensive or technically tricky and could open an opportunity for designing antibodies for targets that have been elusive so far.
- Open Access
RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity
The spread of SARS-CoV-2 has fueled the COVID-19 pandemic with its enduring medical and socioeconomic challenges due to subsequent waves and long-term consequences of great concern. Here we charted the molecular basis of COVID-19 pathogenesis, by analysing patients’ immune response at single-cell resolution across disease course and severity. This approach uncovered cell subpopulation-specific dysregulation in COVID-19 across disease course and severity and identified a severity-associated activation of the receptor for advanced glycation endproduct (RAGE) pathway in monocytes. In vitro experiments confirmed that monocytes bind the SARS-CoV-2 S1-RBD via RAGE and that RAGE-Spike interactions drive monocyte infection. Our results demonstrate that RAGE is a novel functional receptor of SARS-CoV-2 contributing to COVID-19 severity. One-Sentence Summary: Monocyte SARS-CoV-2 infection via the receptor for advanced glycation endproduct triggers severe COVID-19.
Open AccessRAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity
The spread of SARS-CoV-2 has fueled the COVID-19 pandemic with its enduring medical and socioeconomic challenges due to subsequent waves and long-term consequences of great concern. Here we charted the molecular basis of COVID-19 pathogenesis, by analysing patients’ immune response at single-cell resolution across disease course and severity. This approach uncovered cell subpopulation-specific dysregulation in COVID-19 across disease course and severity and identified a severity-associated activation of the receptor for advanced glycation endproduct (RAGE) pathway in monocytes. In vitro experiments confirmed that monocytes bind the SARS-CoV-2 S1-RBD via RAGE and that RAGE-Spike interactions drive monocyte infection. Our results demonstrate that RAGE is a novel functional receptor of SARS-CoV-2 contributing to COVID-19 severity. One-Sentence Summary: Monocyte SARS-CoV-2 infection via the receptor for advanced glycation endproduct triggers severe COVID-19.